Advanced search×

What is the evidence for our standards of care?

Laurence A LA Turka and Arthur A Caplan

J Clin Invest 121(7):2530 (2011) PMID 21737884

The term evidence-based medicine is overused, abused, and is beginning to ring hollow. It is not that evidence (or at least of what most people in biomedicine think evidence-based medicine should strive to be) is a bad thing. Rather, there is more rhetoric about evidence than there is actual evidence to support the degree of talk.

DOI: 10.1172/JCI59185
Version: za2963e q8za6 q8zb1 q8zcf q8zd0 q8ze7 q8zfb q8zga
View PDF

Similar articles you may find interesting…

  1. Absence of Stat1 in donor CD4⁺ T cells promotes the expansion of Tregs and reduces graft-versus-host disease in mice.
    Huihui H Ma, Caisheng C Lu, ... Markus Y MY Mapara

    J Clin Invest 121(7):2554-69 (2011) PMID 21670504

    We used Stat1-deficient mice to test the role of donor Stat1 in MHC-matched minor histocompatibility antigen-mismatched (mHA-mismatched) and fully MHC-mismatched models of bone marrow transplantation. Lack of Stat1 in donor splenocytes reduced graft-versus-host disease (GVHD) in both immunogenetic d...
  2. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
    Seth A Wander, Bryan T Hennessy, and Joyce M Slingerland

    J Clin Invest 121(4):1231-41 (2011) PMID 21490404

    We provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathwa...
  3. Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy.
    Seth A Wander, Bryan T Hennessy, and Joyce M Slingerland

    J Clin Invest 121(4):1231-41 (2011) PMID 21490404

    We provide a brief overview of the signaling pathways up- and downstream of mTORC1 and -2, and discuss the insights into therapeutic anticancer targets - both those that have been tried in the clinic with limited success and those currently under clinical development - that knowledge of these pathwa...
    View PDF